Primary Sclerosing Cholangitis Imaging 

  • Author: Ali Nawaz Khan, MBBS, FRCS, FRCP, FRCR; Chief Editor: John Karani, MBBS, FRCR   more...
 
Updated: May 25, 2011
 

Overview

Primary sclerosing cholangitis (PSC) is a chronic, progressive, inflammatory disease characterized by fibrosis of the bile ducts. The cause is unknown, but a hypersensitivity reaction is implicated. Patients present with abnormalities of liver function tests and progressive intermittent obstructive jaundice, which may be associated with fever chills, night sweats, pain, and itching. A liver biopsy, endoscopic retrograde cholangiopancreatogram (ERCP), or percutaneous cholangiogram can help achieve diagnosis. The term primary is used to distinguish this condition from bile duct strictures that are secondary to bile duct injury, cholelithiasis, ischemia, and chemical injury. The radiologic characteristics of PSC are demonstrated in the images below.[1, 2, 3, 4, 5]

Endoscopic retrograde cholangiopancreatography perEndoscopic retrograde cholangiopancreatography performed in a patient with abnormal liver function test results shows multiple intrahepatic bile duct strictures and beading. Percutaneous transhepatic cholangiogram shows dilaPercutaneous transhepatic cholangiogram shows dilatation, stricturing, and beading of the intrahepatic bile ducts. Note the surgical clips from a previous cholecystectomy. Magnetic resonance cholangiopancreatography shows Magnetic resonance cholangiopancreatography shows a normal-sized common bile duct, but strictures of both the left and right ducts are noted as well as a dilated proximal left hepatic duct.

Preferred examination

Ultrasonography (US) is the initial examination modality of choice in patients presenting with jaundice and right upper quadrant pain. The liver may demonstrate nonspecific abnormalities on US, which infrequently leads to definitive diagnosis. The primary role of US is in helping clinicians make the diagnosis of other bile duct mechanical obstructions, such as gallstones and neoplasia.[6]

ERCP and percutaneous transhepatic cholangiography (PTC) remain the preferred investigations. Advances in software have improved the diagnostic quality of magnetic resonance cholangiopancreatography (MRCP),[7] and although preliminary studies indicate that MRCP may be sensitive and specific in PSC, larger studies are required before it replaces traditional invasive methods.[6, 8, 9, 10, 11, 12, 13]

Limitations of techniques

ERCP and PTC are invasive and can potentially cause ascending cholangitis.[14] Technical advances have improved MRCP such that third- and fourth-order intrahepatic bile ducts can be resolved, but appearances remain nonspecific.

Computed tomography (CT) scans also demonstrate nonspecific changes. Indistinguishable features may occur with cholangiocarcinoma and other forms of cholangitis.

Next

Radiography

Plain radiographs have little role to play in the diagnosis of PSC. Cholangiography in PSC is performed using either PTC or ERCP. ERCP is preferable because of its higher success rate in the absence of dilated intrahepatic bile ducts. (See the images below.)

Endoscopic retrograde cholangiopancreatography perEndoscopic retrograde cholangiopancreatography performed in a patient with abnormal liver function test results shows multiple intrahepatic bile duct strictures and beading. Double-contrast barium enema (same patient as in tDouble-contrast barium enema (same patient as in the previous image) shows filiform polyps and an ahaustral colon resulting from ulcerative colitis. Percutaneous transhepatic cholangiogram shows dilaPercutaneous transhepatic cholangiogram shows dilatation, stricturing, and beading of the intrahepatic bile ducts. Note the surgical clips from a previous cholecystectomy. T-tube cholangiogram shows irregularity of the comT-tube cholangiogram shows irregularity of the common bile duct, stricturing, beading, and dilatation of the intrahepatic bile ducts. Note a calculus in the termination of the left hepatic duct (arrow).

Cholangiographic features of PSC include predominantly intrahepatic ductal disease with short multiple strictures associated with multifocal mild ductal dilations. Cholangiography demonstrates a pruned-tree appearance with filling of the central ducts and diffuse obstruction of the peripheral smaller radicles. More advanced disease is associated with long strictures.

Bile duct dilations may result from the inflammatory process or distal obstruction. Multifocal strictures have a predilection for bifurcations. Skip lesions may be observed in which the duct is of normal caliber.

The above features provide a beaded appearance to the ducts. Coarse nodularity with mural irregularities may produce a cobblestone appearance. Ductal diverticula or pseudodiverticula observed as small saccular outpouchings are pathognomonic findings for PSC.

The common bile duct (CBD) is almost always involved.

The cystic duct also shows strictures, mural nodularity, and dilations with diverticula formation in 18% of patients. Gallbladder irregularity is uncommon. Pancreatic duct strictures and irregularities are observed in 8% of patients.[15]

Intrahepatic pigment calculi, which are easily crushable, are found in 8% of patients and may cause mechanical obstruction. Rarely, these calculi may obstruct the CBD; however, bile duct dilatation may not occur in the presence of cholangiocarcinoma.[15]

Degree of confidence

Appearances of the terminal bile ducts vary, particularly on ERCP, and overinterpretation is common. To tackle this problem, numerous views are obtained at various stages of contrast filling, which may help resolve equivocal changes. Radiographic distinction between a cholangiocarcinoma and sclerosing cholangitis occasionally may be impossible, because the diagnostic specificity of intrahepatic bile duct changes remains controversial.

False positives/negatives

Ascending cholangitis, AIDS-related cholangiopathy, cholangiocarcinoma, chemotherapy-induced cholangitis, eosinophilic cholangitis, recurrent pyogenic cholangitis, cholangitis secondary to parasites, and primary biliary cirrhosis can produce similar radiographic appearances.

Previous
Next

Computed Tomography

Intrahepatic bile duct changes demonstrated on CT scans reflect cholangiography features with pruning and beading of the ducts. Pruning on CT scans is defined as the presence on a single CT slice of a 4-cm or longer segment of dilated duct (excluding the main right and left ducts) that lacks the expected side branching. Beading is defined as at least 3 closely alternating regions of change in caliber in an intrahepatic duct on a single CT slice.

Skip dilatations, defined as isolated dilated peripheral bile ducts with no visible connection to the other dilated ducts on contiguous images, are strongly suggestive of PSC.

CT appearances of extrahepatic bile duct involvement by PSC include focal or diffuse eccentric or concentric involvement and wall thickening (>2 mm and < 5 mm), bile duct dilatation, relative lack of dilatation proximal to an apparent bile duct stricture, and enhancing intraluminal intramural nodules (>1 cm in diameter) seen on thin-section high-resolution images.

Contrast enhancement of the bile duct is a nonspecific finding that can be observed in normal and abnormal bile ducts.

As many as 65% of patients with PSC may have benign celiac, gastrohepatic ligament, porta hepatis, periaortic, pancreaticoduodenal, and mesenteric lymphadenopathy.[16, 17]

Lymph nodes are usually homogeneous and isodense with the pancreas.

Degree of confidence

Intrahepatic bile duct changes on CT scans reflect cholangiographic features with pruning and beading of the ducts. Skip dilatations, defined as isolated dilatation of the intrahepatic bile ducts, are strongly suggestive of PSC; however, ductal delineation and demonstration of strictures can be difficult in the early stages using US or CT scans. CT has a complementary role to that of cholangiography; moreover, do not use CT as a screening examination.

False positives/negatives

Beading, pruning, irregularity, and asymmetry of the intrahepatic bile ducts as demonstrated on CT scans are not specific for PSC. Similar CT changes may be found in other forms of cholangitis and cholangiocarcinoma.

Previous
Next

Magnetic Resonance Imaging

Biliary tract, liver parenchymal, and pancreatic features suggestive of PSC have been reported using MRI.[18, 19]

Use of T1-weighted, fat-suppressed, spin-echo pulse sequences, with or without intravenous gadolinium, facilitates visualization of the bile duct wall. Peripheral, wedge-shaped areas of high T2-weighted signal intensity in the liver parenchyma and dilatation of the bile ducts are characteristic MRI features of PSC observed in approximately 72% of patients.

Associated features include periportal edema (40%), lobar atrophy (8-28%), and portal hypertension (35%).

Abnormal hyperintensity of the liver parenchyma on T1-weighted images may be observed in 23% of patients. Increased enhancement of the liver parenchyma on dynamic arterial-phase gradient-echo images, predominantly in the peripheral areas, may be observed in 56% of patients. Periportal inflammation may be demonstrated on MRI images as a region of low signal intensity on T1-weighted images and as intermediate signal between liver and bile on T2-weighted images.

On gadolinium-enhanced images, enhancement of inflammatory periportal tissue permits distinction from nonenhancing periportal edema.

Characteristic changes on MRI have been recognized within the pancreas, suggestive of PSC. Increased signal on T2-weighted images, decreased signal on T1-weighted images, enlargement of the pancreas, and decreased contrast enhancement are suggestive of pancreatic disease associated with PSC.

MRCP may be used, but the extent of intrahepatic disease may be estimated incorrectly because ductal distension cannot be achieved using this technique. (See the image below.)

Magnetic resonance cholangiopancreatography shows Magnetic resonance cholangiopancreatography shows a normal-sized common bile duct, but strictures of both the left and right ducts are noted as well as a dilated proximal left hepatic duct.

Gadolinium-based contrast agents (gadopentetate dimeglumine [Magnevist], gadobenate dimeglumine [MultiHance], gadodiamide [Omniscan], gadoversetamide [OptiMARK], gadoteridol [ProHance]) have recently been linked to the development of nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD). For more information, see the eMedicine topic Nephrogenic Systemic Fibrosis.

NSF/NFD has occurred in patients with moderate to end-stage renal disease after being given a gadolinium-based contrast agent to enhance MRI or MR angiography (MRA) scans. As of late December 2006, the FDA had received reports of 90 such cases. Worldwide, over 200 cases have been reported, according to the FDA. NSF/NFD is a debilitating and sometimes fatal disease. Characteristics include red or dark patches on the skin; burning, itching, swelling, hardening, and tightening of the skin; yellow spots on the whites of the eyes; joint stiffness with trouble moving or straightening the arms, hands, legs, or feet; pain deep in the hip bones or ribs; and muscle weakness. For more information, see Medscape.

Degree of confidence

The number of patients with PSC who have been studied using MRI has been small; thus, the reliability of the changes described above is uncertain. MRCP may be used, but the extent of intrahepatic disease may be estimated incorrectly because ductal distention cannot be achieved using MRCP.

MRI features of PSC are not specific and may occur with cholangiocarcinoma and other forms of cholangitis.

Previous
Next

Ultrasonography

Ultrasonographically, biliary abnormalities are not usually visible, unless biliary dilatation is associated. Intrahepatic saccular dilations occasionally may be visualized, and in long-standing disease, echogenic intraductal structures, representing sludge or calculi, are visible on US images. Bile duct wall thickening and small intraluminal protrusions also have been reported in patients with PSC. In end-stage disease, US signs of portal hypertension may be demonstrated.

Secondary biliary cirrhosis occurs as a part of the disease complex of PSC. Most patients with secondary biliary cirrhosis have no ultrasonographic abnormalities, but occasionally, irregular segmental duct dilatation can be observed.

Patients with advanced disease may show an increase in periportal echogenicity.

Cirrhotic changes, such as nodularity-increased liver attenuation and splenomegaly, also may be apparent.

Degree of confidence

US appearances of PSC are nonspecific; seldom can a confident diagnosis of PSC be made using US alone. The primary role of US is in the diagnosis of other causes of obstructive jaundice.

False positives/negatives

The differential diagnosis includes cholangiocarcinoma and other causes of ascending cholangitis and primary biliary cirrhosis. In addition to PSC, bile duct wall thickening is associated with hepatic clonorchiasis, recurrent pyogenic cholangitis (Oriental cholangiohepatitis), biliary ascariasis, peribiliary cysts, and AIDS-related cholangiopathy.

Previous
Next

Nuclear Imaging

Radionuclide scanning using technetium-99m (99m Tc) iminodiacetic acid compounds shows multiple focal areas of persistent activity distributed in the liver parenchyma. The clearance rate of the isotope through the liver is markedly prolonged, with gallbladder visualization achieved in 70% of patients.[15, 20] The specificity of99m Tc iminodiacetic acid scanning is low, but it is a valuable technique to use for quantifying biliary kinetics. (See the image below.)

Technetium-99m iminodiacetic acid scan shows retenTechnetium-99m iminodiacetic acid scan shows retention of the radionuclide proximal to strictures in the distribution of the left hepatic duct. Note the lack of filling of the gallbladder because of a previous cholecystectomy. Isotope has entered the small bowel.

Prolonged isotope transit time may occur in other causes of hepatic dysfunction; similarly, nonvisualization of the gallbladder may occur with cystic duct obstruction and chronic gallbladder disease.

Previous
 
Contributor Information and Disclosures
Author

Ali Nawaz Khan, MBBS, FRCS, FRCP, FRCR  Consultant Radiologist and Honorary Professor, North Manchester General Hospital Pennine Acute NHS Trust, UK

Ali Nawaz Khan, MBBS, FRCS, FRCP, FRCR is a member of the following medical societies: American Association for the Advancement of Science, American Institute of Ultrasound in Medicine, British Medical Association, British Society of Interventional Radiology, Royal College of Physicians, Royal College of Physicians and Surgeons of the United States, Royal College of Radiologists, and Royal College of Surgeons of England

Disclosure: Nothing to disclose.

Coauthor(s)

Sumaira MacDonald, MBChB, PhD, MRCP, FRCR  Lecturer, Sheffield University Medical School; Endovascular Fellow, Sheffield Vascular Institute

Sumaira MacDonald, MBChB, PhD, MRCP, FRCR is a member of the following medical societies: British Medical Association, Royal College of Physicians, and Royal College of Radiologists

Disclosure: Nothing to disclose.

Aali J Sheen, MD, MBChB, FRCS  Consulting Hepatobiliary Surgeon, HepatoBiliary Unit, Manchester Royal Infirmary, UK

Aali J Sheen, MD, MBChB, FRCS is a member of the following medical societies: British Medical Association, International Hepato-Pancreato-Biliary Association, and Royal College of Surgeons of England

Disclosure: Nothing to disclose.

Specialty Editor Board

Eric P Weinberg, MD  Associate Professor, Department of Radiology, University of Rochester Medical Center, Strong Memorial Hospital

Eric P Weinberg, MD is a member of the following medical societies: American College of Radiology, American Roentgen Ray Society, and Radiological Society of North America

Disclosure: Nothing to disclose.

Bernard D Coombs, MB, ChB, PhD  Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand

Disclosure: Nothing to disclose.

Arnold C Friedman, MD  FACR, Professor, Department of Radiology, Arizona Health Science Center at the University of Arizona.

Arnold C Friedman, MD is a member of the following medical societies: American College of Radiology, American Institute of Ultrasound in Medicine, American Roentgen Ray Society, Association of University Radiologists, and Radiological Society of North America

Disclosure: Nothing to disclose.

Robert M Krasny, MD  Resolution Imaging Medical Corporation

Robert M Krasny, MD is a member of the following medical societies: American Roentgen Ray Society and Radiological Society of North America

Disclosure: Nothing to disclose.

Chief Editor

John Karani, MBBS, FRCR  Clinical Director of Radiology and Consultant Radiologist, Department of Radiology, King's College Hospital, UK

John Karani, MBBS, FRCR is a member of the following medical societies: British Institute of Radiology, British Society of Interventional Radiology, Cardiovascular and Interventional Radiological Society of Europe, European Society of Gastrointestinal and Abdominal Radiology, European Society of Radiology, Radiological Society of North America, and Royal College of Radiologists

Disclosure: Nothing to disclose.

References
  1. Burak KW, Urbanski SJ, Swain MG. A case of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of autoimmune liver diseases. Dig Dis Sci. Sep 2001;46(9):2043-7. [Medline].

  2. Cameron RG, Blendis LM, Neuman MG. Accumulation of macrophages in primary sclerosing cholangitis. Clin Biochem. May 2001;34(3):195-201. [Medline].

  3. Hawkes ND, Mutimer D, Thomas GA. Intermittent jaundice and rigors in a patient with longstanding ulcerative colitis. Postgrad Med J. Jun 2001;77(908):406-7, 412-3. [Medline].

  4. Schrumpf E, Boberg KM. Primary sclerosing cholangitis: challenges of a new millenium. Dig Liver Dis. Dec 2000;32(9):753-5. [Medline].

  5. Lazaridis KN. Dissecting the genetic susceptibility for cholangiocarcinoma in primary sclerosing cholangitis. Hepatology. Jan 2008;47(1):8-10. [Medline].

  6. Oikarinen H, Paakko E, Suramo I, et al. Imaging and estimation of the prognostic features of primary sclerosing cholangitis by ultrasonography and MR cholangiography. Acta Radiol. Jul 2001;42(4):403-8. [Medline].

  7. Haider MA, Bret PM. The role of magnetic resonance cholangiography in primary sclerosing cholangitis. J Hepatol. Oct 2000;33(4):659-60. [Medline].

  8. Bjornsson ES, Kilander AF, Olsson RG. Bile duct bacterial isolates in primary sclerosing cholangitis and certain other forms of cholestasis--a study of bile cultures from ERCP. Hepatogastroenterology. Nov-Dec 2000;47(36):1504-8. [Medline].

  9. Goolamali SI, Taylor-Robinson SD. Endoscopic retrograde cholangiopancreatography appearances of early primary sclerosing cholangitis. J Clin Gastroenterol. May-Jun 2001;32(5):460-1. [Medline].

  10. Keogan MT, Edelman RR. Technologic advances in abdominal MR imaging. Radiology. Aug 2001;220(2):310-20. [Medline].

  11. Rajaram R, Ponsioen CY, Majoie CB, et al. Evaluation of a modified cholangiographic classification system for primary sclerosing cholangitis. Abdom Imaging. Jan-Feb 2001;26(1):43-7. [Medline].

  12. van den Hazel SJ, Wolfhagen EH, van Buuren HR, et al. Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group. Endoscopy. Oct 2000;32(10):779-82. [Medline].

  13. Etzel JP, Eng SC, Ko CW, Lee SD, Saunders MD, Tung BY. Complications after ERCP in patients with primary sclerosing cholangitis. Gastrointest Endosc. Nov 30 2007;[Medline].

  14. Bangarulingam SY, Gossard AA, Petersen BT, Ott BJ, Lindor KD. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol. Apr 2009;104(4):855-60. [Medline].

  15. Dahnart W. Radiology Review Manual. 6th. Phildelphia: Lippincott William & Wilkins; 2007:699-700.

  16. Hirche TO, Russler J, Braden B, Schuessler G, Zeuzem S, Wehrmann T. Sonographic detection of perihepatic lymphadenopathy is an indicator for primary sclerosing cholangitis in patients with inflammatory bowel disease. Int J Colorectal Dis. Nov 2004;19(6):586-94. [Medline].

  17. Johnson KJ, Olliff JF, Olliff SP. The presence and significance of lymphadenopathy detected by CT in primary sclerosing cholangitis. Br J Radiol. Dec 1998;71(852):1279-82. [Medline].

  18. Fulcher AS, Turner MA, Franklin KJ, et al. Primary sclerosing cholangitis: evaluation with MR cholangiography-a case-control study. Radiology. Apr 2000;215(1):71-80. [Medline].

  19. Elsayes KM, Oliveira EP, Narra VR, Abou El Abbass HA, Ahmed MI, Tongdee R. MR and MRCP in the evaluation of primary sclerosing cholangitis: current applications and imaging findings. J Comput Assist Tomogr. May-Jun 2006;30(3):398-404. [Medline].

  20. Jonas E, Hultcrantz R, Slezak P, et al. Dynamic 99Tcm-HIDA SPET: non-invasive measuring of intrahepatic bile flow. Description of the method and a study in primary sclerosing cholangitis. Nucl Med Commun. Feb 2001;22(2):127-34. [Medline].

Previous
Next
 
Endoscopic retrograde cholangiopancreatography performed in a patient with abnormal liver function test results shows multiple intrahepatic bile duct strictures and beading.
Double-contrast barium enema (same patient as in the previous image) shows filiform polyps and an ahaustral colon resulting from ulcerative colitis.
Percutaneous transhepatic cholangiogram shows dilatation, stricturing, and beading of the intrahepatic bile ducts. Note the surgical clips from a previous cholecystectomy.
T-tube cholangiogram shows irregularity of the common bile duct, stricturing, beading, and dilatation of the intrahepatic bile ducts. Note a calculus in the termination of the left hepatic duct (arrow).
Magnetic resonance cholangiopancreatography shows a normal-sized common bile duct, but strictures of both the left and right ducts are noted as well as a dilated proximal left hepatic duct.
Technetium-99m iminodiacetic acid scan shows retention of the radionuclide proximal to strictures in the distribution of the left hepatic duct. Note the lack of filling of the gallbladder because of a previous cholecystectomy. Isotope has entered the small bowel.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.